知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

126 条记录 (耗时 0.213 秒)

    METHODS OF DIAGNOSING ENDOMETRIOSIS
    4.
    发明申请
    METHODS OF DIAGNOSING ENDOMETRIOSIS 有权
    诊断子宫内膜异位症的方法

    公开(公告)号：US20140024557A1

    公开(公告)日：2014-01-23

    申请号：US14043616

    申请日：2013-10-01

    申请人： The Regents of the University of California

    发明人： Linda C. Giudice

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6883 ,  A61K31/485 ,  A61K31/57 ,  A61K31/60 ,  A61K38/00 ,  C12N15/00 ,  C12N15/11 ,  C12Q1/68 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2333/47 ,  G01N2333/4703 ,  G01N2333/4716 ,  G01N2333/4725 ,  G01N2333/575 ,  G01N2333/96436 ,  G01N2800/364

    摘要： The present invention provides biomarkers for the diagnosis and prognosis of endometriosis. Generally, the methods of this invention find use in diagnosing or for providing a prognosis for endometriosis by detecting the expression levels of biomarkers, which are differentially expressed (up- or down-regulated) in endometrial cells from a patient with endometriosis. Similarly, these markers can be used to diagnose reduced fertility in a patient with endometriosis or to provide a prognosis for a fertility trial in a patient suffering from endometriosis. The present invention also provides methods of identifying a compound for treating or preventing endometriosis. Finally, the present invention provides kits for the diagnosis or prognosis of endometriosis.

    摘要翻译： 本发明提供了用于子宫内膜异位症诊断和预后的生物标志物。 通常，本发明的方法通过检测子宫内膜异位症患者的子宫内膜细胞中差异表达（上调或下调）的生物标志物的表达水平来诊断或提供子宫内膜异位症的预后。 类似地，这些标记物可以用于诊断患有子宫内膜异位症的患者的生育力降低，或者为患有子宫内膜异位症的患者提供生育试验的预后。 本发明还提供鉴定用于治疗或预防子宫内膜异位症的化合物的方法。 最后，本发明提供用于子宫内膜异位症的诊断或预后的试剂盒。

    GRANZYME A AND GRANZYME B DIAGNOSTICS
    5.
    发明申请
    GRANZYME A AND GRANZYME B DIAGNOSTICS 有权
    GRANZYME A和GRANZYME B诊断

    公开(公告)号：US20130323749A1

    公开(公告)日：2013-12-05

    申请号：US13867870

    申请日：2013-04-22

    申请人： The University of British Columbia

    发明人： David Granville ,  Rani Cruz ,  Ciara Chamberlain ,  Wendy Boivin ,  Bruce McManus

    IPC分类号： G01N33/68

    CPC分类号： G01N33/573 ,  G01N33/68 ,  G01N33/6893 ,  G01N2333/96436 ,  G01N2800/065 ,  G01N2800/10 ,  G01N2800/122 ,  G01N2800/20 ,  G01N2800/205 ,  G01N2800/285 ,  G01N2800/323 ,  G01N2800/324

    摘要： A method for identifying a subject being at risk for or having a chronic Inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease is provided. The method may include determining the concentration of GrA and/or GrB in a blood or serum sample from said subject; and comparing the concentrations to the corresponding concentration in a control sample, wherein an elevated concentration of GrA and/or GrB may be indicative of a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease. The method may further include identifying concentrations of fibrinogen, elastin and/or fibrillin.

    摘要翻译： 提供了用于鉴定处于或患有慢性炎症性疾病，原纤维蛋白病，动脉粥样硬化或冠状动脉疾病的风险的受试者的方法。 该方法可以包括确定来自所述受试者的血液或血清样品中的GrA和/或GrB的浓度; 并将浓度与对照样品中相应的浓度进行比较，其中升高的GrA和/或GrB浓度可指示慢性炎性疾病，原纤维蛋白病，动脉粥样硬化或冠状动脉疾病。 该方法还可以包括鉴定纤维蛋白原，弹性蛋白和/或原纤维蛋白的浓度。

    METHODS OF TREATING, REDUCING AND INHIBITING THE APPEARANCE OF AGEING IN THE SKIN
    6.
    发明申请
    METHODS OF TREATING, REDUCING AND INHIBITING THE APPEARANCE OF AGEING IN THE SKIN 审中-公开
    治疗，减少和抑制皮肤老化的方法

    公开(公告)号：US20120171144A1

    公开(公告)日：2012-07-05

    申请号：US12282157

    申请日：2007-03-09

    申请人： David James Granville ,  Rani Priya Gomez Cruz

    发明人： David James Granville ,  Rani Priya Gomez Cruz

    IPC分类号： A61K8/64 ,  A61Q19/08 ,  C12Q1/37 ,  A61Q5/00

    CPC分类号： A61K8/64 ,  A61K2800/782 ,  A61Q5/10 ,  A61Q7/00 ,  A61Q19/007 ,  A61Q19/08 ,  C12Q1/37 ,  G01N2333/96436

    摘要： Methods of treating, reducing and inhibiting the appearance of ageing in the skin are provided. Also provided are uses and methods of maintaining a youthful appearance, reducing an appearance of ageing, inhibiting an appearance of ageing, reducing a rate of an appearance of ageing, reducing a skin inelasticity, reducing a rate of increasing skin inelasticity, maintaining a skin elasticity, and increasing the density of hair follicles of a skin of a subject comprising applying a granzyme B inhibitor to the skin of the subject. Also provided are methods of identifying a granzyme B inhibitors and agonists.

    摘要翻译： 提供了治疗，减少和抑制皮肤老化外观的方法。 还提供了保持年轻外观，减少老化外观，抑制老化外观，降低老化外观速度，降低皮肤无弹性，降低皮肤弹性不足率，保持皮肤弹性的用途和方法 并且增加受试者皮肤的毛囊的密度，包括将颗粒酶B抑制剂施用于受试者的皮肤。 还提供了鉴定颗粒酶B抑制剂和激动剂的方法。

    Inhibitor of interaction of granzyme b with golgin-160
    8.
    发明申请
    Inhibitor of interaction of granzyme b with golgin-160 审中-公开
    粒酶b与golgin-160相互作用的抑制剂

    公开(公告)号：US20070116694A1

    公开(公告)日：2007-05-24

    申请号：US10544461

    申请日：2004-06-16

    申请人： Hirofumi Doi ,  Masahiro Ezaki ,  Shoichi Masuda ,  Tomoya Miyagawa

    发明人： Hirofumi Doi ,  Masahiro Ezaki ,  Shoichi Masuda ,  Tomoya Miyagawa

    IPC分类号： A61K38/54 ,  A61K38/48

    CPC分类号： C07K14/47 ,  A61K38/08 ,  A61K38/17 ,  A61K38/1709 ,  C12N9/6467 ,  G01N2333/96436 ,  G01N2500/02

    摘要： It is an object of the present invention to find a protein interacting with Granzyme B and to provide a means for preventing and/or treating diseases caused by the decomposition of the above protein by Granzyme B. The present invention provides a method of using Golgin-160 as a substrate of Granzyme B; a method for screening an inhibitor of the interaction of Granzyme B with Golgin-160 and/or an inhibitor of the decomposition of Golgin-160 by Granzyme B; various types of agent which comprise an inhibitor of the interaction of Granzyme B with Golgin-160 and/or an inhibitor of the decomposition of Golgin-160 by Granzyme B; and a method for preventing and/or treating various diseases which comprises a step of inhibiting the interaction of Granzyme B with Golgin-160 and/or the decomposition of Golgin-160 by Granzyme B.

    摘要翻译： 本发明的目的是找到与颗粒酶B相互作用的蛋白质，并提供预防和/或治疗由颗粒酶B分解上述蛋白质引起的疾病的方法。本发明提供了使用Golgin- 160作为颗粒酶B的底物; 筛选Granzyme B与Golgin-160和/或Granzyme B分解Golgin-160抑制剂的抑制剂的方法; 包含Granzyme B与Golgin-160相互作用抑制剂和/或Granzyme B分解Golgin-160抑制剂的各种试剂; 以及用于预防和/或治疗各种疾病的方法，其包括抑制颗粒酶B与Gingin-160的相互作用和/或由Granzyme B分解Golgin-160的步骤。

    Molecular dissection of cellular responses to alloantigen or autoantigen in graft rejection and autoimmune disease
    9.
    发明申请
    Molecular dissection of cellular responses to alloantigen or autoantigen in graft rejection and autoimmune disease 审中-公开
    细胞对同种异体抗原或自身抗原在移植排斥反应和自身免疫疾病中的分子解剖

    公开(公告)号：US20060263343A1

    公开(公告)日：2006-11-23

    申请号：US11433776

    申请日：2006-05-15

    申请人： Norma Kenyon ,  Cynthia Healy ,  Steven Koester ,  Xiumin Xu

    发明人： Norma Kenyon ,  Cynthia Healy ,  Steven Koester ,  Xiumin Xu

    IPC分类号： C12Q1/68 ,  G01N33/567 ,  A61K48/00 ,  A61K39/395 ,  A61K31/573 ,  A61K31/7048 ,  A61K31/4745 ,  G01N33/53 ,  A61K39/00

    CPC分类号： G01N33/56972 ,  G01N33/564 ,  G01N33/6863 ,  G01N2333/96436 ,  G01N2800/24 ,  G01N2800/245

    摘要： An antigen-specific T-cell response to alloantigen, tissue-specific antigen (e.g., islet antigen or other autoantigens involved in autoimmune disease), or self (or host) antigen is detected at an early stage of graft rejection or recurrent autoimmunity. An increase in cytotoxic lymphocyte gene (CLG) expression in peripheral blood is a risk factor for development of deleterious immune responses, which may be confirmed by functional assays. For example, the distinction between production of regulatory or inflammatory cytokines by T cells may dissect the type of immune response which is being induced: the survival of transplanted islet cells used to treat type 1 diabetes may be monitored, loss of the transplant by graft rejection (i.e., an alloantigen target) may be distinguished from autoimmune disease (i.e., a self or host antigen target).

    摘要翻译： 在移植排斥反应或复发性自身免疫的早期阶段检测抗同种异体抗原，组织特异性抗原（例如，参与自身免疫疾病的胰岛抗原或其他自身抗原）或自身（或宿主）抗原的抗原特异性T细胞应答。 外周血中细胞毒性淋巴细胞基因（CLG）表达的增加是有害免疫应答发展的危险因素，这可以通过功能测定来证实。 例如，由T细胞产生调节性炎性细胞因子或炎性细胞因子之间的区别可能会解剖正在诱导的免疫应答的类型：可以监测用于治疗1型糖尿病的移植胰岛细胞的存活，移植物排斥的丧失 （即，同种异体抗原靶）可以与自身免疫疾病（即自身或宿主抗原靶）区分开。